Brigham Heart & Vascular at ACC 2024

Brigham and Women’s Hospital will have a strong presence at this year’s American College of Cardiology (ACC) 2024 Scientific Session & Expo, held April 6–8 in Atlanta, GA.

Thousands of international colleagues will gather at ACC 2024 to network with one another and learn the latest advances in the field of cardiology. Participants will have access to over 300 educational sessions and late-breaking clinical research across 11 learning pathways.

Physicians and researchers from the Brigham Heart & Vascular Center will present their cutting-edge research at the event, covering a wide range of topics in cardiovascular care with a global health perspective.

Learn more about the event and register here.

Brigham Participants

Saturday, April 6

Cardiogenic Shock Epidemiology in Cardiac Intensive Care Units (CICUS) Using the Framework of the Shock Academic Research Consortium (SHARC) Consensus Definitions
Session 1201, Hall B4-5: 9:45 a.m.
David D. Berg, MD, MPH

Use of Palliative Care Services in Patients With Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN) Registry
Session 1201, Hall B4-5: 9:45 a.m.
Daniel McClintick, MD

Adverse Cardiovascular Events Among Younger and Older Patients Referred for Coronary CTA: The Mass General Brigham CCTA Registry
Session 1007, Moderated Poster Theater 07: 10:30 a.m.
Daniel M. Huck, MD, MPH

Contemporary Nationwide Patterns of Oral Anticoagulant Use in the U.S.: NHANES 2009 to 2020
Session 1235, Hall B4-5: 10:45 a.m.
Rahul Aggarwal, MD

Low Absolute Risk of Thrombotic and Major Cardiovascular Events in Outpatient Pregnant Women With COVID-19
Session 1021, Moderated Poster Theater 09: 11:30 a.m.
Behnood Bikdeli, MD, MS

The Association of Immune-mediated Inflammatory Disease and Lipoprotein(a) With Major Adverse Cardiovascular Events Among Individuals With and Without Baseline Atherosclerotic Cardiovascular Disease: The Mass General Brigham Lp(a) Registry
Session 1020, Moderated Poster Theater 08: 11:45 a.m.
Brittany Weber, MD, PhD

Assessment of Bleeding and Thrombotic Risk: Are Existing Tools Sufficient?
Session 608, Hall B407: 12:00 p.m.
Michelle L O’Donoghue, MD, MPH

Fibrosis in the Fontan Patient, Looking Beyond the Liver; Does Fibrosure Data Predict Clinical Outcomes?
Session 1018, Moderated Poster Theater 06: 12:00 p.m.
Anne Valente, MD

Cardiovascular Benefit of Evolocumab in 27,564 Patients With and Without Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial
Session 1020, Moderated Poster Theater 08: 12:00 p.m.
Andre Zimerman, MD, PhD

Efficacy of Icosapent Ethyl for Reducing Cardiovascular Outcomes by Baseline Low Density Lipoprotein Cholesterol Level
Session 1020, Moderated Poster Theater 08: 12:15 p.m.
Rahul Aggarwal, MD

Igniting the Spark: Inspiring Students to Pursue a Journey in Congenital Cardiology
Session 609, B308: 12:26 p.m.
Anne Valente, MD

Pump Problems: IABP Rupture, Impella Alarms, Hemolysis, Oh My!
Session 606, Hall B405: 12:37 p.m.
Erin A. Bohula May, MD, DPhil

Data-driven Decisions for LM Revascularization
Session 605, Hall B402: 12:47 p.m.
Brian A. Bergmark, MD

Effects of Sacubitril/Valsartan in Patients With Heart Failure Across the Spectrum of Kidney Risk
Session 910 – Young Investigators Awards: Clinical Investigations, Engage Stage: 1:30 p.m.
Muthiah Vaduganathan, MD, MPH

Optimizing Phenotyping Algorithms for Identifying Pulmonary Embolism in Electronic Databases: The Multicenter PE-EHR+ Study
Session 1283, Hall B4-5: 1:45 p.m.
Behnood Bikdeli, MD, MS

Should Frail Elderly AF Patients on VKA Switch to a DOAC? A Randomized Comparison From COMBINE-AF, a Patient-level Metanalysis of the 4 Large RCTS of DOACs VS Warfarin
Session 1029, Moderated Poster Theater 05: 2:15 p.m.
Robert Giugliano, MD, ScM

Frailty Status and Outcomes in 58,634 Patients With Atrial Fibrillation Randomized to DOAC VS Warfarin
Session 1025, Moderated Poster Theater 01: 2:30 p.m.
Andre Nicolau, MD

Poster Moderator: New and Novel Updates in Pharmacotherapy for Ischemic Heart Disease
Session 1042, Moderated Poster Theater 06: 3:30 p.m.
Benjamin Scirica, MD

Sex Differences in Treatment Strategies for Pulmonary Embolism in Older Adults: The SERIOUS-PE Study
Session 1322, Hall B4-5: 3:45 p.m.
Behnood Bikdeli, MD, MS

Concurrent Evaluation of HSTNI and HSTNT and Their Associations With Cardiovascular Events in 37,886 Patients With Stable Atherosclerotic Cardiovascular Disease
Session 1324, Hall B4-5: 3:45 p.m.
Rohan Bajaj, MD

Master Clinician Panelist: A Parade of Patients: Real-time Decision-making in Chest Pain Patients With Imaging Experts and Master Clinicians
Session 644, B216: 4:15 p.m.
David Morrow, MD, MPH

Optimal Follow-up Strategies for Patients After Large PE: Best Practice
Session 638, B309: 4:25 p.m.
Umberto Campia, MD

Sunday, April 7

Zilebesiran in Combination With a Standard-of-Care Antihypertensive in Patients With Inadequately Controlled Hypertension – Primary Results From the Phase 2 KARDIA-2 Study
Session 405 – Late-Breaking Clinical Trials II, Hall B-1 Main Tent: 8:00 a.m.
Akshay Desai, MD, MPH

“If You Build It, They Will Come” Building a Cardio-Oncology Program
Session 652, B206: 8:00 a.m.
Anju Nohria, MD, MSc

Year in Review: Pediatric and Congenital Heart Disease
Session 902, B308: 8:00 a.m.
Anne Valente, MD

Efficacy and Safety of Olezarsen in Patients With Hypertriglyceridemia and High Cardiovascular Risk: Primary Results of the BRIDGE-TIMI 73a Trial
Session 405 – Late-Breaking Clinical Trials II, Hall B-1 Main Tent: 8:30 a.m.
Brian A. Bergmark, MD

New AFIB in the Office: Which Patients Can I Manage as an Outpatient and Who Needs to Go to the ER?
Session 659, B312: 9:45 a.m.
Lindsay Harris, NP

Session Co-Chair: Highlighted Original Research: Ischemic Heart Disease and the Year in Review
Session 906, B402: 9:45 a.m.
Benjamin Scirica, MD

SGLT2 Inhibitors and Major Adverse Cardiovascular Events in Patients With Diabetes at High Risk for Atherosclerotic Cardiovascular Disease, Heart Failure or Chronic Kidney Disease: A SMART-C Collaborative Meta-analysis
Session 1372, Hall B4-5: 10:15 a.m.
Siddharth Patel, MD

Deep Learning-Based Electrocardiogram Analysis to Predict Biventricular Dysfunction and Dilation in Congenital Heart Disease
Session 1066, Moderated Poster Theater 06: 11:30 a.m.
Anne Valente, MD

Learning Destination Presenter: The Equity in Heart Transplant Project: Breaking Down Barriers to Heart Transplantation
Session 4715, Health Equity Hub: 11:30 a.m.
Tracy Makuvire, MD

The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Study: A Randomized Evaluation of a Team-based Remote Education and Medication Management Program to Reduce CV and Kidney Risk
Session 407, Hall B-1 Main Tent: 12:30 p.m.
Alexander Blood, MD

Effect of DOACs Versus Warfarin By ASCVD Status in 58,634 Patients With Atrial Fibrillation: A Pooled Analysis of 4 Randomized Trials
Session 1423, Hall B4-5: 1:15 p.m.
Andre Zimerman, MD, PhD

Identification of Atrial Fibrillation Patients With Favorable Outcomes on Warfarin: An Individual Patient-level Analysis of 29,272 Warfarin Patients From the COMBINE-AF Study
Session 1423, Hall B4-5: 1:15 p.m.
Samer Al Said, DrMed, MD

Detection of Hypertrophic Cardiomyopathy on Electrocardiogram Using Artificial Intelligence
Session 1462, Hall B4-5: 3:15 p.m.
James Hills, MD

Adjudicated Cardiovascular Events in Patients With COVID-19: Association With Vaccination Status and Changes Over Time in the CORONA-VTE Network Study
Session 1463, Hall B4-5: 3:15 p.m.
Behnood Bikdeli, MD, MS

Prognostic Value of Myocardial Flow Reserve Versus Corrected Myocardial Flow Reserve in Patients Without Obstructive Coronary Artery Disease
Session 1091, Moderated Poster Theater 07: 4:00 p.m.
Daniel M. Huck, MD, MPH

Monday, April 8

Valentin Fuster Award for Innovation in Science
Peter Libby, MD, FACC

Soluble Suppression of Tumorigenicity 2 (SST2) and Cardiovascular Outcomes in Persons With Type 2 Diabetes Mellitus Randomized to Dapagliflozin or Placebo: Analyses From the DECLARE-TIMI 58 Trial
Session 1099, Moderated Poster Theater 03: 9:15 a.m.
Paul Haller, MD, PhD

In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After a Worsening Heart Failure Event: The PARAGLIDE-HF Trial
Session 1099, Moderated Poster Theater 03: 9:30 a.m.
Nina Nouhravesh, MD

Early Changes in Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Registry
Session 1105, Moderated Poster Theater 09: 9:30 a.m.
Siddharth Patel, MD

Lipoprotein(a) As a Cardiovascular Risk Factor Among Patients With and Without Diabetes Mellitus: The Mass General Brigham Lp(a) Registry
Session 1492, Hall B4-5: 9:45 a.m.
Arthur Shiyovich, MD

Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial
Session 1098, Moderated Poster Theater 02: 10:00 a.m.
Maria Pabon Porras, MD

Promise Minimal Risk Score in Young Individuals With Myocardial Infarction: From the MGB YOUNG-MI Registry
Session 1512, Hall B4-5: 10:45 a.m.
Avinainder Singh, MD, MMSc

Session Co-Chair: Back to the Future: What Did 2023 Teach Us About Ischemic Heart Disease Care Post-Pandemic
Session 730, B401: 11:00 a.m.
Benjamin Scirica, MD

Session Co-Chair: Upstairs Management of MCS and Shock
Session 732, B405: 11:00 a.m.
Erin A. Bohula May, MD, DPhil

Sotagliflozin Reduces Stroke Outcomes in Patients With Diabetes and Chronic Kidney Disease
Session 1116, Hall B4-5: 12:15 p.m.
Rahul Aggarwal, MD

Session Panelist: The Intersection Between Burnout, End-of-Life Issues, and Team Engagement in the CCU
Session 754, B211: 12:45 p.m.
Erin A. Bohula May, MD, DPhil

Long-term Evolocumab in Elderly Patients With Established Atherosclerotic Cardiovascular Disease: Analysis From FOURIER and FOURIER-OLE
Session 1551, Hall B4-5: 12:45 p.m.
Samer Al Said, DrMed, MD

Leave a Reply